Osteoporosis

Last reviewed: 26 Apr 2022
Last updated: 29 Jul 2020

Summary

Definition

History and exam

Other diagnostic factors

  • back pain
  • kyphosis
  • impaired vision
  • impaired gait, imbalance, and lower-extremity weakness
  • vertebral tenderness
Other diagnostic factors

Risk factors

  • prior fragility fracture
  • female sex
  • white ancestry
  • older age (>50 years for women and >65 years for men)
  • low BMI
  • loss of height
  • family history of maternal hip fracture
  • postmenopause
  • secondary amenorrhea
  • primary hypogonadism
  • tobacco use
  • excessive alcohol use
  • prolonged immobilization
  • low calcium intake
  • vitamin D deficiency
  • glucocorticoid excess
  • corticosteroid use
  • proton-pump inhibitors
  • hyperthyroidism
  • heparin use
  • anticonvulsant use
  • weight loss >10% body weight
  • androgen deprivation treatment (men)
  • aromatase inhibitor treatment (women)
More risk factors

Diagnostic investigations

1st investigations to order

  • dual-energy x-ray absorptiometry (DXA)
More 1st investigations to order

Investigations to consider

  • Fracture Risk Assessment Tool (FRAX)
  • quantitative ultrasound (QUS) of the heel
  • x-ray (wrist, heel, spine, and hip)
  • quantitative CT
  • biochemical markers of bone resorption and bone formation
  • serum alkaline phosphatase
  • serum calcium
  • serum albumin
  • serum creatinine
  • serum phosphate
  • serum 25-hydroxy vitamin D
  • serum parathyroid hormone
  • thyroid function tests
  • urinary free cortisol
  • serum testosterone (men)
  • urine protein electrophoresis
  • serum protein electrophoresis
More investigations to consider

Treatment algorithm

ONGOING

not glucocorticoid-induced: women

not glucocorticoid-induced: men

glucocorticoid-induced

Contributors

Authors

Khashayar Sakhaee, MD

Professor in Internal Medicine

Division Chief of Mineral Metabolism

Center for Mineral Metabolism and Clinical Research

UT Southwestern Medical Center at Dallas

Dallas

TX

Disclosures

KS declares that he has no competing interests.

Alberto V Cabo Chan Jr., MD

Assistant Professor

Internal Medicine

University of Texas Southwestern

Dallas

TX

Disclosures

AVCC declares that he has no competing interests.

Acknowledgements

Dr Khashayar Sakhaee and Dr Alberto V Cabo Chan Jr. would like to gratefully acknowledge Dr Lisa Leinau, a previous contributor to this topic.

Disclosures

LL declares that she has no competing interests.

Peer reviewers

Kimberly Olson, MD

Internist

Veterans Administration Hospital

Minneapolis

MN

Disclosures

KO declares that she has no competing interests.

David Reid, MBBS

Head of Division of Applied Medicine & Professor of Rheumatology

School of Medicine & Dentistry

University of Aberdeen

Aberdeen

UK

Disclosures

DMR has attended meetings sponsored by or been paid speaker fees by Amgen, Merck, Novartis, Procter & Gamble, Roche, and Servier. He has been a paid advisor to Amgen, Merck, Novartis, Procter & Gamble, Roche, Servier, and Shire Pharmaceuticals. He has undertaken research studies funded by Amgen, Merck, Novartis, Procter & Gamble, and Roche.

  • Osteoporosis images
  • Differentials

    • Multiple myeloma
    • Osteomalacia
    • Chronic kidney disease-bone and mineral disorder
    More Differentials
  • Guidelines

    • Pharmacological management of osteoporosis in postmenopausal women
    • Screening for osteoporosis to prevent fractures
    More Guidelines
  • Patient leaflets

    Osteoporosis: what is it?

    Osteoporosis: what treatments work?

    More Patient leaflets
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer